30 closest matches · ranked by relevance
Hunter Syndrome
Primary: Infusion-Related Adverse Event (IRAE) Rates Between IgG Anti-idursulfase Antibody Positive (Ab+) and Anti-idursulfase IgG Antibody Negative (Ab-) Patients — 0.0121…
HIV
Primary: The Proportion of Patients Achieving Undetectable Viral Loads at Week 24. — 44; 28 percentage of participants
Multiple Myeloma
Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants
Gaucher Disease
Primary: Number of Patients With GD Diagnosis Confirmed by : Enzyme Testing of acidβ-glucosidase Activity Activity <15% in Blood Leucocytes Completed When Necsssary by GB1…
Systemic Lupus Erythematosus (SLE) · Juvenile SLE · Cutaneous Lupus
Primary: Serum Levels of Thalidomide — 415.1 ng/mL
HIV-1-infection
Primary: Safety of TMB-365 and TMB-380 Given Intravenously (Sentinel and Core) — 0; 0; 0; 0 Participants
Diabetes Mellitus, Type 1
Primary: Change in Mean C-peptide Area Under the Curve (AUC) Response to a Mixed Meal Tolerance Test (MMTT) — -0.28; -0.46 pmol/mL — p=0.002
HPV Seroconversion
Primary: Number of Participants With Geometric Mean Antibody Concentrations by HPV Type — 15; 12; 8; 4 Participants
Antibody-mediated Rejection · Hyperacute Rejection of Cardiac Transplant · Left Ventricular Dysfunction
Primary: Number of Participants of Pathologic Antibody-Mediated Rejection and Left Ventricular Dysfunction — 4 Participants
Drug-specific Antibodies · Diabetes Mellitus
Primary: Percentage of Participants With Treatment-emergent Anti-Drug Antibody (ADA) — 0; 2.0 percentage of participants
Cocaine Dependence
Primary: Cocaine Intoxication — 59; 51; 45; 44 units on a scale
Rheumatoid Arthritis
Primary: Percentage of Participants Positive for Antidrug Antibodies Among Those Treated With Etanercept Versus Those Treated With Monoclonal Antibodies (Adalimumab or…
Rheumatoid Arthritis
Primary: Total Number of Patients With Adverse Events — 27.8 Percentage of Patients
Mucopolysaccharidosis I
Primary: Number of Participants Who Achieved Immune Tolerance Induction — 0; 1 participants
Churg-Strauss Syndrome · Eosinophilic Asthma · Eosinophilic Esophagitis
Primary: Number and Percentage of Patients With a Positive Autoantibody ELISA — 19; 4; 3; 4 Participants
Other Complication of Kidney Transplant · Renal Transplant Rejection
Primary: Cases of Kidney Transplant Patients With DSA — 0; 0 Participants
Human Immunodeficiency Virus
Primary: Grade 3 and Serious Adverse Events — 0 Participants
Human Cancers
Primary: Serious Adverse Events (SAEs) and Non-serious Adverse Events (AEs) Considered to be at Least Possibly Related to MOv18 IgE — 0; 5; 2; 0 Participants
Melanoma
Primary: Toxicity — 1; 1; 6; 1 participants
Adenocarcinoma
Primary: Overall Survival — 15.7; 9.0 months — p=0.0024
Paraneoplastic Syndromes
Primary: Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus — 48 months
History of IgE Dependent Reaction to a Penicillin Product
Primary: Negative Predictive Value — 98.0 percentage of participants
Methamphetamine-dependence · Methamphetamine Abuse
Primary: Change in Plasma Methamphetamine (METH) Area Under the Curve (AUCinf) Resulting From METH Challenge Doses Following Single IV Doses of IXT-m200 — 1635; 1433; 1265; 1233…
Chronic Lung Disease
Primary: Number and Percentage of Participants With Immune Reactivity — 0; 1; 1; 0.0 Participants
Neuromyelitis Optica · Neuromyelitis Optica Spectrum Disorder
Primary: Change in Neurological Disability - Expanded Disability Scale Score — 4.0; 6.5; 6.5; 4.0 EDSS unit score
Immunologic Tests
Primary: Number of Subject Responders With Antigen Specific Lymphocytes T Helper 2 (Th2) Cluster of Differentiation 4+ (CD4+) T Cells Expressing Cytokines — 7; 1; 7; 0 Subjects
Antibody-mediated Rejection · Kidney Transplant; Complications · Transplant Glomerulopathy
Primary: Number of Participants With Donor Specific Antibody (DSA) Elimination or Reduction Based on Luminex HLA Testing — 7 Participants
HIV
Primary: Safety and Tolerability of Ibalizumab + OBR — 8; 9 participants
Renal Transplant Rejection
Primary: Change in Biopsy Cell Densities From Baseline to Follow-up — -164; -122.5; -129.4; 30.4 cells/mm^3 — p=0.25
Chronic Obstructive Pulmonary Disease · Emphysema
Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change